GLSI
Greenwich LifeSciences, Inc.
Next earnings Aug 12, 2026 · consensus $-0.34 EPS
$19.80
▲ +8.02%$19.80▲ +122.47%
over 1Y
L $7.85EODHDH $33.57
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.0%
1W-16.6%
1M-32.3%
3M-11.3%
YTD+1.7%
1Y+122.5%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
High leverage (liabilities/equity 7.2x).
Greenwich LifeSciences, Inc. shows limited reported revenue, and -5480.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$4.60M | -$8.04M | -$9.33M | -$17.6M | -$19.4M |
| Net income | -$4.57M | -$7.83M | -$8.89M | -$17.4M | -$19.4M |
| Diluted EPS | — | -$0.61 | -$0.69 | -$1.34 | -$1.43 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$284M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-6.7%
FCF yield—
Quality & risk
ROIC (est.)-4349.7%
Free cash flow—
Total debt—
Net cash$6.18M
Piotroski F-Score2/6
Capital returns
Buyback yield2.6%
Dividend yield (est.)—
Shareholder yield2.6%
Shares Δ YoY+10.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-03-31). Worth a closer look.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-06-04open ↗10-KPeriod ending 2025-12-312026-06-01open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗4Period ending 2026-01-132026-01-15open ↗4Period ending 2026-01-122026-01-14open ↗4Period ending 2025-12-312026-01-05open ↗4Period ending 2025-12-302026-01-02open ↗4Period ending 2025-12-182025-12-19open ↗8-KPeriod ending 2025-12-182025-12-18open ↗4Period ending 2025-11-252025-11-28open ↗4Period ending 2025-11-132025-11-17open ↗10-QPeriod ending 2025-09-302025-11-14open ↗
Frequently asked
- Is Greenwich LifeSciences, Inc. (GLSI) a buy?
- GLSI currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. High leverage (liabilities/equity 7.2x).
- What is Greenwich LifeSciences, Inc.'s quality score?
- GLSI scores 29/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001799788, latest 10-Q filed 2026-06-04) · EODHD · as of 6/26/2026, 12:22:22 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.